共 48 条
[1]
Jager RD(2008)Age-related macular degeneration N Engl J Med 358 2606-2617
[2]
Mieler WF(2012)Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010 Am J Ophthalmol 153 209-213
[3]
Miller JW(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[4]
Bloch SB(2013)Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany Acta Ophthalmol 91 540-546
[5]
Larsen M(2015)Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration Br J Ophthalmol 99 220-226
[6]
Munch IC(2014)Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research Graefes Arch Clin Exp Ophthalmol 252 647-655
[7]
Rosenfeld PJ(2015)Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany Ophthalmologe 112 246-254
[8]
Brown DM(2012)Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 171-185
[9]
Heier JS(2012)Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2537-2548
[10]
Finger RP(2017)Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany. Twelve-month outcomes of PERSEUS Ophthalmol Retina 2 539-549